Tag Archive for: Editas

Data show the potential of Editas’ sickle cell disease and transfusion-dependent beta thalassemia gene therapy candidate, but it might not be enough to overtake Vertex and CRISPR Therapeutics.

With 2022 in the books, many in the biopharma industry are looking back at the year that’s passed and noticing trends that may help predict what’s to come in 2023.